ALPN
NASDAQAlpine Immune Sciences, Inc.
Healthcare · Biotechnology
Price History
Learn Why It Moved
Educational concepts related to this stock
Volume Surge
Unusual trading volume indicates heightened interest — institutional activity or news-driven demand.
Biotech Catalyst
Biotech stocks are often driven by FDA approvals, trial results, and regulatory news. Learn how binary catalysts work.
Insider Activity
Check if insiders have been buying or selling. Insider buying is one of the strongest signals in small cap trading.
Dilution Risk
Check SEC filings for active shelf registrations. Dilution is the #1 risk in small cap trading.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.